Last reviewed · How we verify
Minoxidil 5% Topical Solution
Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle.
Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle. Used for Androgenetic alopecia (male pattern baldness), Female pattern hair loss.
At a glance
| Generic name | Minoxidil 5% Topical Solution |
|---|---|
| Also known as | Regaine® |
| Sponsor | Triple Hair Inc |
| Drug class | Potassium channel opener |
| Target | ATP-sensitive potassium channels (KATP) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Minoxidil acts as a vasodilator by opening ATP-sensitive potassium channels, which increases cutaneous blood flow to hair follicles and delivers more oxygen and nutrients to the dermal papilla. This stimulation extends the anagen phase of hair growth and may increase hair follicle size, promoting hair regrowth in androgenetic alopecia. The exact mechanism in hair growth remains incompletely understood but involves both vascular and direct follicular effects.
Approved indications
- Androgenetic alopecia (male pattern baldness)
- Female pattern hair loss
Common side effects
- Scalp irritation
- Dryness of scalp or skin
- Itching
- Unwanted hair growth on adjacent skin
- Dermatitis
Key clinical trials
- Androgenic Alopecia TH07 Clinical Trial (PHASE3)
- Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia (NA)
- Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia (PHASE2)
- A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes (PHASE1, PHASE2)
- Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (PHASE4)
- Minoxidil for Treating White Hair: A Randomized Controlled Trial (PHASE4)
- A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia. (PHASE2)
- Treatment of Androgenetic Alopecia in Men for 24 Weeks (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minoxidil 5% Topical Solution CI brief — competitive landscape report
- Minoxidil 5% Topical Solution updates RSS · CI watch RSS
- Triple Hair Inc portfolio CI